Commercializing Continuous Processing in Pharma Summit CCP on March 26-28, 2024 in Boston, United States

The 8th CCP Summit is the longest-standing industry-focused and cross-modality meeting, delving into the scientific and strategic challenges that have the potential to significantly expedite the adoption and scale-up of continuous processing.

Carefully curated in collaboration with industry leaders, the summit offers a content-rich experience with cutting-edge presentations from leading pharma and biotech. Over the course of three days of unmissable content across small molecules, biologics and new addition of ATMPs, this forum will harmoniously pair technical case studies with the business-case-realities to leave you with the definitive answer of why NOT continuous processing. As adaption and acceptance of this innovative technology gathers speed, accompanied by enhanced regulatory guidance from the FDA and ICH Q13, the 8th CCP Summit will unite 140+ senior stakeholders. They will share insights into their continuous manufacturing journeys, providing inspiration to overcome pressing challenges to accelerate quality drug products speed-to-market through end-to-end continuous manufacturing implementation.

URLs:

Brochure: https://go.evvnt.com/2118793-2?pid=10008

Tickets: https://go.evvnt.com/2118793-3?pid=10008

Time: 8:30 am - 3:45 pm

Prices:

Drug Developers - Conference + 2 Workshops + Site Visit: USD 4197.00,

Drug Developers - Conference + 2 Workshops: USD 4197.00,

Drug Developers - Conference + 1 Workshop + Site Visit: USD 3598.00,

Drug Developers - Conference + 1 Workshop: USD 3598.00,

Drug Developers - Conference + Site Visit: USD 2999.00,

Drug Developers - Conference Only: USD 2999.00,

Service Providers - Conference + 2 Workshops + Site Visit: USD 5097.00,

Service Providers - Conference + 2 Workshops: USD 5097.00,

Service Providers - Conference + 1 Workshop + Site Visit: USD 4398.00,

Service Providers - Conference + 1 Workshop: USD 4398.00

Speakers: Anna Bay, Senior Scientist I, Abbvie, Atul Dubey Sr., Principal Scientist, U.S. Pharmacopeia, Ciby Abraham, Senior Director and Group Manager, Project and Product Leadership Chemistry, Manufacturing and Controls Regulatory Affairs, AstraZeneca, Daniel Griffin, Principal Engineer, Amgen, Darren Whitaker, Senior Staff Engineer – Process Chemistry R and D, Takeda, Edita Botonjic-Sehic, Project Lead, MIT-FDA, Fred Ohsiek, Senior Manager - Validation Life Sciences, Ecolab Ltd, Guanghui Zhu, Senior Staff Engineer, Takeda, Hasin Feroz, Senior Scientist, Moderna, Irina Ramos, Director - Bioprocess Technology and Engineering, AstraZeneca, Ken Lee, Director, Bioprocess Technologies and Engineering, Biopharmaceuticals, AstraZeneca, Lawrence De Belder, Continuous Processing SME, Pharamtech Associates, Manuel Carrondo, Vice President - Business Strategy, IBET - Instituto de Biologia Experimental e Tecnologica, Michael Frederick, Senior Director - Synthetic Molecule Design and Development, Eli Lilly and Co., Ravendra Singh, Professor Department of Chemical and Biochemical Engineering, Rutgers University, Richard Braatz, Associate Director and Professor - Chemical Engineering, MIT, Robert Yule, Head Of Process Operations, Data and Modelling, Sanofi, Sayantan Chattorajz, Process Engineering and Analytics, Drug Product Development, GSK, Sean Daughtry, Director - Technical Operations and Analytical, Vertex Pharmaceuticals, Simon Coleman, Isolation and Drying Product Manager, Dec Group, Stephen Born, Director of Scientific Affairs, CONTINUUS Pharmaceuticals, Steve Lathrop, Senior Process Engineer, Pfizer, Sune Klint, Andersen Principal Scientist, Janssen